Editorial Review

Kidney International (1986) 29, 469–477; doi:10.1038/ki.1986.23

Potential role of platelet-activating factor in renal pathophysiology

Giovanni Camussi1

1Torino, Italy

Correspondence: Dr G Camussi, Department of Pathology, 208 Forber Hall, State University of New York at Buffalo, Buffalo, New York 14214, USA

Received 8 April 1985; Revised 6 August 1985.

Top

References

  1. Benveniste J, Henson PM, Cochrane CG: Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils and a platelet-activating factor. J Exp Med 136:1356–1377, 1972 | Article | PubMed | ISI | ChemPort |
  2. Benveniste J, Tence M, Varenne P, Bidault J, Boullet C, Polonsky I: Semisynthese et structure proposee du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidilcholine. CR Acad Sci (Paris) 289:1037–1040, 1979
  3. Demopoulos CA, Pinckard RN, Hanahan DJ: Platelet-activating factor. Evidence for 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (A new class of lipid chemical mediators). J Biol Chem 254:9355–9358, 1979 | PubMed | ISI | ChemPort |
  4. Findley SR, Lichtenstein LM, Hanahan DJ, Pinckard RN: The contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. Am J Physiol 241:C130–C133, 1981
  5. Stimler NP, Bloor CM, Hugli TE, Wykle RL, McCall CE, O'Flaherty JR: Anaphylactic actions of platelet activating factor. Am J Pathol 105:64–69, 1981
  6. Burke JA, Levi R, Hanahan DS, Pinckard RM: Cardiac effects of acetyl glyceryl ether phosphorylcholine (abstract). Fed Proc 41:823, 1982
  7. Benveniste J, Boullet C, Brink C, Labat C: The actions of PAF-aceter (platelet-activating factor) on guinea pig isolated heart preparations. Br J Pharmacol 80:81–85, 1983
  8. Camussi G, Alloatti C, Montrucchio G, Meda M, Emanuelli G: Effect of platelet-activating factor on guinea pig papillary muscle. Experientia 40:697–699, 1984
  9. Camussi G, Tetta C, Bussolino F, Caligaris-Cappio F, Masera C, Segoloni G: Mediators of immune complex induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int Archs Allergy Appl Immun 64:25–41, 1981 | ChemPort |
  10. Shaw JO, Pinckard RN, Ferrigni KS, McManus L, Hanahan DJ: Activation of human neutrophils with 1-0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). J Immunol 127:1250–1255, 1981 | PubMed |
  11. Yasaka T, Boxer LA, Baehner RL: Monocytes aggregation and superoxide anion release in response to formylmethyionyl-leucylphenyalanine (FMLP) and platelet activating factor (PAF). J Immunol 128:1939–1944, 1982
  12. McManus LM, Pinckard RN, Fitzpatrick FA, O'Rourke RA, Crawford MH, Hanahan DJ: Acetyl glyceryl ether phosphorylcholine. Intravascular alterations following intravenous infusion into the baboon. Lab Invest 45:303–307, 1981 | PubMed | ChemPort |
  13. Sánchez-Crespo M, Alonso F, Iñarrea P, Alvarez V, Egido J: Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. Immunopharmacology 4:173–185, 1982
  14. Humphrey DM, Hanahan DJ, Pinckard RN: Induction of leukocytic infiltrates in rabbit skin by acetyl glyceryl ether phosphorylcholine. Lab Invest 47:227–234, 1982
  15. Bonnet J, Loiseau AM, Orvoen M, Bessin P: Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. Agents Act 11:559–561, 1981
  16. Humphrey DM, McManus L, Satouchi K, Hanahan DJ, Pinckard RN: Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogs. Lab Invest 46:422–427, 1982 | PubMed | ChemPort |
  17. Pinckard RN, Kniker WT, Lee L, Hanahan DJ, McManus LM: Vasoactive effects of 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) in human skin (abstract). J Allergy Clin Immunol 65:196, 1980
  18. Humphrey DM, McManus L, Hanahan DJ, Pinckard RN: Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine. Lab Invest 50:16–25, 1984
  19. Camussi G, Tetta C, Coda R, Segoloni G, Vercellone A: Platelet activating factor-induced loss of glomerular anionic charges. Kidney Int 25:73–81, 1984 | PubMed |
  20. Muirhead EE, Byers LN, Desiderio DM, Brooks BB, Brosius WM: Antihypertensive lipids from the kidney: alkyl ether analogs of phosphatidylcholine. Fed Proc 40:2285–2290, 1981
  21. Halonen M, Palmer JD, Lohman IC, McManus LM, Pinckard RN: Respiratory and circulatory alterations induced by acetyl glyeryl ether phosphorylcholine (AGEPC), a mediator of IgE anaphylaxis in the rabbit. Am Rev Resp Dis 122:915–924, 1980
  22. Halonen M, Palmer JD, Lohman IC, McManus LM, Pinckard RN: Differential effects of platelet depletion on the cardiovascular and pulmonary alterations of IgE anaphylaxis and AGEPC infusion in the rabbit. Am Rev Resp Dis 124:416–421, 1981
  23. Mencia-Huerta JM, Benveniste J: Platelet activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol 9:409–415, 1979
  24. Camussi G, Aglietta M, Coda R, Bussolino F, Piacibello W, Tetta C: Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology 42:191–199, 1981 | PubMed | ISI | ChemPort |
  25. Camussi G, Bussolino F, Tetta C, Piacibello W, Aglietta M: Biosynthesis and release of platelet-activating factor from human monocytes. Int Archs Allergy Appl Immun 70:245–251, 1983
  26. Lotner GZ, Lynch JM, Betz SJ, Henson PM: Human neutrophil-derived platelet activating factor. J Immunol 124:676–684, 1980
  27. Chignard M, LeCouedic JP, Tence M, Vargaftig BB, Benveniste J: The role of platelet-activating factor in platelet aggregation. Nature 279:799–800, 1979 | Article | PubMed | ISI | ChemPort |
  28. Camussi G, Aglietta M, Malavasi F, Tetta C, Piacibello W, Sanavio F, Bussolino F: The release of platelet-activating factor from human endothelial cells in culture. J Immunol 131:2397–2403, 1983 | PubMed | ChemPort |
  29. Prescott SM, Zimmerman GA, McIntyre TM: Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) when stimulated with thrombin. Proc Natl Acad Sci USA 81:3534–3538, 1984 | Article | PubMed | ChemPort |
  30. Camussi G, Mencia-Huerta JM, Benveniste J: Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology 33:523–534, 1977
  31. Pirotzky E, Bidault J, Buctin C, Guber MC, Benveniste J: Release of platelet-activating factor, slow-reacting substance and vasoactive amines from isolated rat kidneys. Kidney Int 25:404–410, 1984 | PubMed | ChemPort |
  32. Henson PM: Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen. J Exp Med 131:287–306, 1970 | Article | PubMed |
  33. Betz SJ, Lotner GZ, Henson PM: Generation and release of platelet-activating factor (PAF) from enriched preparations of rabbit basophils; failure of human basophils to release PAF. J Immunol 125:2749–2755, 1980
  34. Lynch JM, Lotner GZ, Betz SJ, Henson PM: The release of platelet-activating factor by stimulated rabbit neutrophils. J Immunol 123:1219–1226, 1979
  35. Camussi G, Pawlowski I, Bussolino F, Caldwell P, Brentjens J, Andres G: Release of platelet-activating factor in rabbits with antibody mediated injury of the lung. The role of polymorphonuclear neutrophils and pulmonary endothelial cells. J Immunol 131:1802–1806, 1983
  36. Pirotzky E, Misumi J, Boullet C: Libération du facteur activant les plaquettes (P.A.F.-acéther) par perfusion du rein isolé de rat. CR Acad Se (Paris) 290 SD:1079–1082, 1980
  37. Camussi G, Tetta C, Deregibus MC, Bussolino F, Segoloni G, Vercellone A: Platelet-activating factor (PAF) in experimentally-induced rabbit acute serum sickness: role of basophil-derived PAF in immune complex deposition. J Immunol 128:86–94, 1982
  38. Blank ML, Snyder F, Byers LW, Brooks B, Muirhead E: Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Comm 30:1134–1200, 1979
  39. Muirhead EM, Germain GS, Armstrong FB, Brooks B, Leach BE, Byers LW, Pitcock JA, Brown P: Endocrine-type antihypertensive function of renomedullary interstitial cells. Kidney Int 8:271–282, 1975
  40. Pirotzky E, Ninio E, Bidault J, Pfister A, Benveniste J: Biosynthesis of platelet-activating factor. VI. Precursor of platelet-activating factor and acetyltransferase activity in isolated rat kidney cells. Lab Invest 51:567–572, 1984
  41. Pirotzky E, Bidault J: Formation of PAF-aceter by rat kidneys, in Platelet-activating Factor, INSERM Symposium No. 23, edited by Benveniste J, Arnouxs B, Amsterdam, Amsterdam Elsevier Scientific Publishers BV, 1983, pp 117–122
  42. Wykle RL, Malone B, Snyder F: Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine, a hypotensive and platelet-aggregating lipid. J Biol Chem 255:10256–10260, 1980 | PubMed | ChemPort |
  43. Vargaftig BB, Chignard M, Benveniste J, Lefort J, Wol F: Background and present status of research on platelet-activating factor (PAF-acether). Ann NY Acad Sci USA 370:119–137, 1981
  44. Henson PM: Activation of rabbit platelets by platelet activating factor (PAF) derived from IgE-sensitized basophils. Characteristics of the aggregation and its dissociation from secretion. J Clin Invest 60:481–490, 1977
  45. Shaw JO, Klusick SJ, Hanahan DJ: Activation of rabbit platelet phospholipase and thromboxane synthesis by 1-0-hexadecyl/octadecyl-2-acetyl-3-phosphorylcholine (platelet activating factor). Biochim Biophys Acta 663:222–229, 1981
  46. Camussi G, Arese P, Tetta C, Bussolino F, Coda R, Vercellone A: Platelet activating factor, in Glomerular Injury 300 Years after Morgagni, edited by Bertani T, Remuzzi G, Milano, Wichting Ed., 1983, pp 89–118
  47. Valone FH, Coles E, Reinhard VR, Goetzel EJ: Specific binding of phospholipid platelet-activating factor by human platelets. J Immunol 129:1637–1644, 1982
  48. Valone FH, Johnson B: Modulation of cytoplasmic calcium in human platelets by the phospholipid platelet activating factor 1-0-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine. J Immunol 134:1120–1124, 1985
  49. Lapetina EG: Action of platelet-activating factor on lipid metabolism and protein phosphorylation of platelets, in Platelet-activating Factor, INSERM Symposium No. 23, edited by Benveniste J, Arnoux B, Amsterdam, Amsterdam Elsevier Scientific Publishers, 1983, pp 125–134
  50. Chilton FH, O'Flaherty JT, Walsh CE, Thomas MJ, Wykle RL, DeChatelet LR, Waite BM: Platelet activating factor. Stimulation of the lipoxigenase pathway in polymorphonuclear leuckoytes by 1-0-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine. J Biol Chem 257:5402–5407, 1982
  51. Lin AH, Morton DR, Gorman RR: Acetyl glyceryl ether phosphorylcholine stimulate leukotriene B4 synthesis in human polymorphonuclear leukocytes. J Clin Invest 70:1058–1065, 1982 | PubMed | ChemPort |
  52. Valone FH, Goetzl EJ: Specific binding by human polymorphonuclear leukocytes of the immunological mediator 1-0-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. Immunology 48:141–147, 1983 | PubMed | ChemPort |
  53. Camussi G, Montrucchio G, Antro C, Bussolino F, Tetta C, Emanuelli G: Platelet activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. Immunopharmacology 6:87–96, 1983
  54. Cerrino J, Raffestin B, Labat C, Boullet C, Bayol A, Gateau O, Brink C: Effect of PAF-aceter on isolated muscle preparation from rat, guinea-pig and human lung, in Platelet-activating Factor, INSERM Symposium No. 23, edited by Benveniste J, Arnoux B, Amsterdam, Amsterdam Elsevier Scientific Publishers, 1983, pp 205–212
  55. Prancan A, Lefort J, Barton M, Vargaftig B: Relaxation of the guinea-pig trachea induced by platelet-activating factor and by serotonin. Eur J Pharmacol 80:29–35, 1982
  56. Schlondorff D, Satriano JA, Hagege J, Perez J, Baud L: Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release and contraction of cultured rat mesangial cells. J Clin Invest 74:1227–1231, 1984
  57. Sedor JR, Abboud HE: Platelet-activating factor stimulates oxygen radical release by culture rat mesangial cells (abstract). Kidney Int 27:222, 1985
  58. McManus LM, Hanahan DJ, Demopoulos CA, Pinckard RN: Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC) a synthetic platelet activating factor (PAF) in the rabbit. J Immunol 124:2919–2924, 1980
  59. Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I, Benveniste J: Acute circulatory collapse caused by platelet-activating factor (PAF-aceter) in dogs. Eur J Pharmacol 86:403–413, 1983 | Article | PubMed | ISI | ChemPort |
  60. Bessin P, Bonnet J, Thibaudeon J, Agier B, Beand Y, Gilet F: Pathophysiology of shock states caused by PAF-acether in dogs and rats, in Platelet-activating Factor, INSERM Symposium No. 23, edited by Benveniste J, Arnoux B, Amsterdam, Amsterdam Elsevier Scientific Publishers BV., 1983, pp 343–355
  61. Pinckard RN, Farr RS, Hanahan DJ: Physiocochemical and functional identity of rabbit platelet activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE-sensitized basophils. J Immunol 123:1847–1857, 1979
  62. Henson PM, Pinckard RN: Basophil derived platelet-activating factor (PAF) as an in vivo mediator of acute allergic reactions. Demonstration of specific densensitization of platelets to PAF during IgE-induced anaphylaxis in the rabbit. J Immunol 119:2179–2184, 1977
  63. Henson PM, Cochrane CG: Acute immune complex disease in rabbits. The role of complement and of a leukocyte-dependent release of vasoactive amines from platelets. J Exp Med 133:554–571, 1971 | Article | PubMed | ISI | ChemPort |
  64. Barnes JL, Venkatachalam MA: Enhancement of glomerular immune complex deposition by a circulating poly cation. J Exp Med 160:284–293, 1984
  65. Ito S, Camussi G, Tetta C, Milgrom F, Andres G: Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab Invest 51:148–161, 1984
  66. Camussi G, Tetta C, Segoloni G, Coda R, Vercellone A: Localization of neutrophil cationic proteins and loss of anionic charges in glomeruli of patients with systemic lupus erythrematosus glomerulonephritis. Clin Immunol Immunopathol 24:299–314, 1982
  67. Caramelo C, Fernández-Gallardo S, Marin-Cao D, Iñarrea P, Santos JC, López-Noroa JM, Sánchez-Crespo M: Presence of platelet-activating factor in blood from humans and experimental animals—Its absence in anephric individuals. Biochem Biophys Res Comm 120:789–796, 1984
  68. Sánchez-Crespo M, Iñarrea P, Alvarez V, Alonso F, Egido J, Hernando L: Presence in normal human urine of a hypotensive and platelet-activating phospholipid. Am J Physiol 244:F706–F711, 1983 | PubMed | ChemPort |
  69. Muirhead EE: Depressor functions of the kidney. Sem Nephrol 3:14–29, 1983

Extra navigation

.
ADVERTISEMENT